MedTrace Logo

Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)

NCT00264147 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 761

Last updated 2022-02-09

Study results available
· View outcomes & findings →

Summary

To assess the clinically active dose range of study medication in the treatment of patients with rheumatoid arthritis.

Conditions

Interventions

DRUG

etoricoxib

Period I: Arm 1: etoricoxib 10 mg tablet once daily. 12 weeks of treatment.

DRUG

etoricoxib

Period I: Arm 2: etoricoxib 30 mg tablet once daily. 12 weeks of treatment.

DRUG

etoricoxib

Period I: Arm 3: etoricoxib 60 mg tablet once daily. 12 weeks of treatment.

DRUG

etoricoxib

Period I: Arm 4: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.

DRUG

Comparator: placebo

Period I: Arm 5: Pbo tablet once daily. 12 weeks of treatment.

DRUG

etoricoxib

Period II: Arm 1: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.

DRUG

Comparator: diclofenac

Period II: Arm 2: diclofenac 75 mg tablet twice daily. 12 weeks of treatment.

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-03-31
Completion
2008-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00264147 on ClinicalTrials.gov